Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Jyoti D. Patel et al.|New England Journal of Medicine|2020Cited by 835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid CancerKeith C. Bible, Carol K. Wong-Clark, Electron Kebebew et al.|Thyroid|2021Cited by 699
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Megan Othus et al.|Clinical Cancer Research|2020Cited by 326
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with <i>RET</i>-altered cancers.Alexander Drilon, Lori J. Wirth, Vivek Subbiah et al.|Journal of Clinical Oncology|2018Cited by 104